The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Hum Vaccin Immunother. 2023 Dec 15;19(3):2269794. doi: 10.1080/21645515.2023.2269794. Epub 2023 Oct 26.
This study aims to summarize and visually analyze the current research status in pancreatic cancer immunotherapy during the past two decades by bibliometrics and explore the current research hotspots and future development directions. The literature related to pancreatic cancer immunotherapy from 2002 to 2021 was downloaded from the core database of the Web of Science. VOSviewer and CiteSpace software were used to visualize the included literature. A total of 2528 articles were included. In the past two decades, publications in the pancreatic cancer immunotherapy field have increased almost annually. As the country with the largest publications, the United States has various research institutions dedicated to pancreatic cancer immunotherapy. Jaffee EM and Zheng L from Johns Hopkins University and Vonderheide RH from the University of Pennsylvania have published the most articles in this field. The current research hotspots of pancreatic cancer immunotherapy include the tumor microenvironment, immune cells, immune checkpoint blockade, and combination therapy. The study of novel immunotherapies and combination therapy may become the primary focus of future research on pancreatic cancer immunotherapy. More prospective clinical studies with high evidence levels should be conducted.
本研究旨在通过文献计量学总结和直观分析过去二十年中胰腺癌免疫治疗的研究现状,并探讨当前的研究热点和未来的发展方向。从 2002 年到 2021 年,从 Web of Science 的核心数据库中下载了与胰腺癌免疫治疗相关的文献。使用 VOSviewer 和 CiteSpace 软件对纳入的文献进行可视化。共纳入 2528 篇文章。在过去的二十年中,胰腺癌免疫治疗领域的出版物几乎每年都在增加。美国作为发表文献最多的国家,拥有各种专注于胰腺癌免疫治疗的研究机构。约翰霍普金斯大学的 Jaffee EM 和 Zheng L 以及宾夕法尼亚大学的 Vonderheide RH 在该领域发表的文章最多。目前胰腺癌免疫治疗的研究热点包括肿瘤微环境、免疫细胞、免疫检查点阻断和联合治疗。新型免疫疗法和联合疗法的研究可能成为未来胰腺癌免疫治疗研究的主要焦点。应该开展更多具有高证据水平的前瞻性临床研究。
Hum Vaccin Immunother. 2023-12-15
Healthcare (Basel). 2023-1-19
Front Immunol. 2023
Front Immunol. 2024
Hum Vaccin Immunother. 2024-12-31
J Gastrointest Cancer. 2025-4-22
Int Immunopharmacol. 2022-7
Nat Rev Drug Discov. 2022-7
Cancer Res. 2021-12-15
Expert Opin Ther Targets. 2021-11
J Immunother Cancer. 2021-8
Nat Rev Gastroenterol Hepatol. 2021-7
Cancer Discov. 2021-4
Zhonghua Wai Ke Za Zhi. 2021-2-1